Projet COLOTAN (Horizon 2020, appel à projets 2020)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

The Colon Targeting Network (COLOTAN) is a European Training Network that will train 13 Early Stage Researchers (ESRs) in (bio)pharmaceutical sciences to improve targeting of oral drugs to the colon. Oral administration of drugs is the preferred delivery route due to its non-invasiveness and convenience for the patient. However, issues related to solubility, absorption, and metabolism often cause oral drug candidate attrition. Oral formulations that release the drug in a pH- or time-dependent manner in the colon have been developed for local treatment of colonic diseases. However, currently available colon-targeting formulations suffer from an inconsistent performance and lack of efficiency due to intra- and interindividual (patho)physiological variability. Moreover, the available tools to predict drug absorption mainly focus on the upper gastrointestinal tract and fail to recapitulate events occurring in the colon, resulting in a lack of validated models to predict drug and formulation behaviour in the colon. To meet these challenges, we must move beyond traditional, mainly monodisciplinary education and train a new generation of pharmaceutical scientists in diverse disciplines ranging from drug delivery to chemistry, cell biology, microbiology and gastroenterology. In an ambitious intersectoral environment, COLOTAN will deliver this new generation via an advanced research and training programme with a total value of 180 ECTS comprising challenging Individual Research Projects, workshops with joint training in scientific and transferable skills, online training, individual training, dissemination, outreach and career development activities. At the end of the project, all ESRs will obtain a doctoral degree. This new generation of ESRs will become future leaders in academia and industry and will be at the forefront of developing a new generation of innovative colon targeting drugs.

Mots clés : drug delivery, new formulations, pharmaceutical technology, biopharmacy, pharmacokinetics, drug, absorption, gastroenterology, colon, gut microbiota, pharmacometrics, pbpk models, in vitro models

Participants :
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 281982.96 €
- National University of Ireland (Irlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274684.32 €
- University of Copenhagen (Danemark) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 297522.0 €
- University of Parma (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 261499.68 €
- KU Leuven (Belgique) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 512640.0 €
- Uppsala University (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 845948.88 €
- Janssen (Belgium) (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 256320.0 €
- University of London (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 303172.56 €
- National and Kapodistrian University of Athens (Grèce) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 243017.64 €
- Seps pharma (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 256320.0 €